BridgeBio Pharma (BBIO) Other Non Operating Income (2018 - 2026)

BridgeBio Pharma has reported Other Non Operating Income for 7 years, with the latest figure at $21.2 million in Q4 2025.

• Quarterly Other Non Operating Income changed N/A year-over-year to $21.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $21.2 million (up 157.02% YoY) and the FY2024 annual result came in at -$26.6 million, changed N/A from the prior year.
• Other Non Operating Income advanced to $21.2 million in Q4 2025 per BBIO's latest filing, from $8.2 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $28.3 million in Q4 2021 and troughed at -$26.6 million in Q1 2024.
• A 4-year average of $2.8 million and a median of $4.6 million in 2022 frame the typical range for Other Non Operating Income.
• The widest YoY moves for Other Non Operating Income: up 1116.46% in 2021, down 7700.0% in 2021.
• Over 4 years, Other Non Operating Income stood at $28.3 million in 2021, then sank by 83.88% to $4.6 million in 2022, then sank by 683.11% to -$26.6 million in 2024, then jumped by 179.56% to $21.2 million in 2025.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $21.2 million, $8.2 million, and -$26.6 million for Q4 2025, Q1 2025, and Q1 2024 respectively.